These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 2176346

  • 21. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
    Lancaster SG, Todd PA.
    Drugs; 1988 Jun; 35(6):646-69. PubMed ID: 2844497
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical experience with lisinopril. Observations on safety and tolerability.
    Cameron HA, Higgins TJ.
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():177-86. PubMed ID: 2550641
    [Abstract] [Full Text] [Related]

  • 24. [Inhibitors of angiotensin-converting enzyme in cardiac insufficiency].
    Amodeo C.
    Arq Bras Cardiol; 1990 Feb; 54(2):97-9. PubMed ID: 2175595
    [No Abstract] [Full Text] [Related]

  • 25. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
    Ionescu SD, Sandru V, Leuciuc E, Manea P, Burdujan A, Tovarniţchi S, Cosovanu A.
    Rev Med Chir Soc Med Nat Iasi; 2002 Feb; 106(1):128-31. PubMed ID: 12635373
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience.
    Navookarasu NT, Rahman AR, Abdullah I.
    Int J Clin Pract; 1999 Feb; 53(1):25-30. PubMed ID: 10344062
    [Abstract] [Full Text] [Related]

  • 31. Angiotensin-converting enzyme inhibitors: are there significant clinical differences?
    Jessup M.
    J Am Coll Cardiol; 1989 May; 13(6):1248-50. PubMed ID: 2539404
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ.
    Clin Physiol Biochem; 1988 May; 6(3-4):217-29. PubMed ID: 2849521
    [Abstract] [Full Text] [Related]

  • 34. [Effect of captopril and lisinopril on adrenergic receptor density and serum norepinephrine and epinephrine in patients with congestive heart disease].
    Halawa B.
    Pol Tyg Lek; 1988 May; 48(3-4):77-9. PubMed ID: 8395686
    [Abstract] [Full Text] [Related]

  • 35. Angiotensin converting enzyme inhibitor therapy.
    Róna G.
    Ther Hung; 1991 May; 39(2):63-70. PubMed ID: 1948779
    [Abstract] [Full Text] [Related]

  • 36. Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring.
    Herpin D, Conte D.
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():11-5. PubMed ID: 2550634
    [Abstract] [Full Text] [Related]

  • 37. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
    Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE.
    Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.